[The efficacy of eltrombopag plus cyclosporine A in patients with transfusion-dependent non-severe aplastic anemia: a retrospective study from single center].

Abstract

The main purpose of our study was to evaluate the efficacy and safety of eltrombopag plus cyclosporine A (CsA) in transfusion-dependent non-severe aplastic anemia(TD-NSAA). The clinical characteristics of 13 TD-NSAA patients who received initial treatment of eltrombopag plus CsA from 2019 to 2021 were retrospectively analyzed. The 3-month overall hematological response (OR) rate was 12/13. Until the end of follow-up, 12 patients responded, among whom 2 patients reached complete response (CR) and 9 patients reached partial response (PR) and 1 with HR. Paroxysmal nocturnal hemoglobinuria (PNH) developed in one patient at 6 months after treatment. Five of thirteen patients reported mild adverse reactions, which were all manageable. Compared with historical data, the combination of eltrombopag with CsA is an effective regimen in patients with TD-NSAA.

• Authors: Y Chen, Q Zha, F Huang, C Qiao, Y Wang, R Wang, J Y Li, W Y Shen
• Journal: Zhonghua nei ke za zhi (Zhonghua Nei Ke Za Zhi) Vol. 61 Issue 4 Pg. 409-411 (Apr 01 2022) ISSN: 0578-1426 [Print] China
• PMID: 35340188 (Publication Type: Journal Article)

Chemical References

• Antilymphocyte Serum
• Benzoates
• Hydrazines
• Immunosuppressive Agents
• Pyrazoles
• Cyclosporine
• eltrombopag

Topics

• Anemia, Aplastic (drug therapy)
• Antilymphocyte Serum (therapeutic use)
• Benzoates
• Cyclosporine (therapeutic use)
• Humans
• Hydrazines
• Immunosuppressive Agents (therapeutic use)
• Pyrazoles
• Retrospective Studies